Synthio Labs Raises $5 Million Seed Round Led by Elevation Capital to Build Voice AI Platform for Life Sciences
Synthio Labs, a clinical-grade voice AI startup focused on transforming engagement across the life sciences industry, has raised $5 million in a seed funding round to accelerate product development and expand its global operations. The round was led by Elevation Capital, with participation from 1984 Ventures, Peak XV Partners, and Y Combinator, alongside several strategic angel investors with backgrounds in healthcare and artificial intelligence.
Founded in 2024 by Supreet Deshpande, Sahitya Sridhar, and Rajashekar Vasantha, Synthio Labs is building what it describes as a voice AI operating system designed specifically for life sciences companies. The platform is intended to support compliant, real-time communication between pharmaceutical and biotech organizations and their key stakeholders, including physicians, healthcare professionals, and patients. By focusing on the strict regulatory and quality requirements of healthcare, Synthio aims to deliver AI-driven engagement tools that can be deployed at enterprise scale.
Synthio’s product portfolio includes Jarvis, a clinical-grade voice AI copilot that supports field teams in managing workflows and customer interactions; Ather, a multimodal AI engine that powers omnichannel engagement across voice, text, and other digital interfaces; and Simulation Studio, which enables the creation of high-fidelity digital twins of healthcare professionals and patients. These digital simulations are designed to help life sciences companies test engagement strategies, train teams, and generate insights in controlled environments before deploying them in real-world settings.
The founding team brings experience from both the life sciences and technology sectors, having worked on commercial strategy, consulting, and AI system development in previous roles. This combination of domain expertise and technical depth has shaped Synthio’s focus on building infrastructure that can operate reliably in regulated environments, where data privacy, accuracy, and compliance are critical. The company positions its technology as an alternative to fragmented engagement models that rely heavily on manual outreach and disconnected tools.
The $5 million in seed funding will be used to expand Synthio Labs’ engineering and product teams across the United States and India, scale enterprise deployments, and deepen partnerships with pharmaceutical and healthcare organizations in major global markets. The company has reported early adoption by several top-tier pharmaceutical companies and digital-first healthcare brands, indicating demand for more scalable and consistent engagement solutions.
Synthio has highlighted examples of large-scale deployments to demonstrate the capabilities of its platform. In one instance, its voice AI system was used to reach thousands of eczema patients within a short period, managing onboarding, screening, and follow-up interactions automatically. Such use cases are intended to show how AI-driven voice engagement can handle high volumes while maintaining consistency and adherence to clinical and regulatory standards.
Investor interest in Synthio Labs reflects a broader trend toward vertical-specific AI platforms that address well-defined industry problems. Elevation Capital’s leadership in the round signals confidence in the company’s vision of creating foundational engagement infrastructure for life sciences, while participation from 1984 Ventures, Peak XV Partners, and Y Combinator brings a mix of early-stage support and experience scaling technology companies globally.
The life sciences sector spends billions annually on customer engagement across sales, marketing, and patient support, yet many organizations continue to face challenges related to reach, personalization, and efficiency. Synthio Labs aims to address these challenges by offering a unified voice and multimodal AI platform that can operate continuously, capture structured insights from conversations, and reduce the operational burden on human teams.
As Synthio Labs continues to build out its technology and customer base, the company is positioning itself to play a central role in how pharmaceutical and biotech companies engage with clinicians and patients. With fresh capital and backing from established investors, Synthio plans to focus on scaling its platform, expanding enterprise adoption, and demonstrating the long-term impact of AI-powered voice engagement in regulated healthcare environments.
